Bupropion and Citalopram in the APP23 Mouse Model of Alzheimer's Disease: A Study in a Dry-Land Maze. (29th September 2012)

• Record Type: Journal Article
• Authors: Neumeister, Katharina L.; Riepe, Matthias W.
• Other Names: Panza Francesco Academic Editor.
• Is Part Of: International journal of alzheimer's disease. Volume 2012(2012)
• Publication Date: 2012-09-29
• Subjects: Alzheimer's disease -- Periodicals; 616.831005
• DOI: 10.1155/2012/673584
• Languages: English
• ISSNs: 2090-8024

Abstract

Abstract : Background . Incipient Alzheimer's disease is often disguised as depressive disorder. Over the course of AD, depressive symptoms are even more frequent. Hence, treatment with antidepressants is common in AD. It was the goal of the present study to assess whether two common antidepressants with different mechanisms of action affect spatial learning in a transgenic animal model of Alzheimer's disease. Methods . We assessed spatial memory of male wild-type and B6C3-Tg(APPswe, PSEN1dE9)85Dbo (APP23) transgenic animals in a complex dry-land maze. Animals were treated with citalopram (10 mg/kg) and bupropion (20 mg/kg). Results . Moving and resting time until finding the goal zone decreased in 4.5-month-old sham-treated wild-type animals and, to a lesser extent, in APP23 animals. Compared with sham-treated APP23 animals, treatment with bupropion reduced resting time and increased speed. On treatment with citalopram, moving and resting time were unchanged but speed decreased. Length of the path to the goal zone did not change on either bupropion or citalopram. Conclusion . Bupropion increases psychomotor activity in APP23 transgenic animals, while citalopram slightly reduces psychomotor activity. Spatial learning per se is unaffected by treatment with either bupropion or citalopram.